Skip to content

Quality Control of CE-Certified Phonak Hearing Aids - 2017_37

Quality Control of CE-Certified Phonak Hearing Aids - 2017_37

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03379766
Enrollment
20
Registered
2017-12-20
Start date
2018-01-08
Completion date
2018-02-02
Last updated
2018-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hearing Loss, Sensorineural

Brief summary

Phonak Hearing Systems pass through different development and study stages. At an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner. If the benefit is proven, their performance is then investigated regarding interdependency between all available algorithms, features and functions running in parallel in a hearing aid (pivotal/pre-validation studies) and, as a result, they get optimized. Afterwards, and prior to product launch, the Phonak Hearing Systems undergo a final quality control in terms of clinical trials. This is a pre-validation study, investigating optimized algorithms, features and functions. This will be a clinical evaluation which will be conducted mono centric at Sonova AG Headquarters based in Stäfa (Switzerland).

Interventions

DEVICESuccessor of Phonak Audéo B-Direct

The successor of Phonak Audéo B-Direct will be fitted to the participants indivudal hearing loss.

DEVICEPhonak Audéo B-Direct

The Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.

Sponsors

Sonova AG
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult hearing impaired persons (minimum age: 18 years) with at least 3 months experience with hearing aids * Good written and spoken (Swiss) German language skills * Healthy outer ear * Ability to fill in a questionnaire (p/eCRF) conscientiously * Informed Consent as documented by signature

Exclusion criteria

* Contraindications to the MD in this study, e.g. known hypersensitivity or allergy to the investigational product * Limited mobility and not in the position to attend weekly appointments in Stäfa (Switzerland) * Limited ability to describe listening impressions/experiences and the use of the hearing aid * Inability to produce a reliable hearing test result * Massively limited dexterity * Known psychological problems * Central hearing disorders

Design outcomes

Primary

MeasureTime frameDescription
Spontaneous acceptance of the initial pre-calculation (first fit)One weekThe data, serving as primary outcomes are collected in the first study appointment. The spontaneous acceptance of the initial pre-calculation (also called 'first fit') in regard to loudness and sound quality will be assessed with the aid of a systematic interview in lab.

Secondary

MeasureTime frameDescription
Listening effort in noisy listening environmentOne weekThe data, serving as secondary outcomes are collected in the second study appointment. The listening effort in noisy listening environments will be assessed under controlled conditions in lab with the aid of the Adaptive Categorial Listening Effort Scaling Test (ACALES). The result shows the listening effort on a scale from 'no effort - extreme effort' at different signal to noise ratios.
Speech intelligibility in noisy listening environmentOne weekThe data, serving as secondary outcomes are collected in the third study appointment. The speech intelligibility in noise will be assessed with the aid of the german Oldenburg sentence test (OLSA) under controlled conditions in lab. The result is the signal to noise ratio in dB (dB SNR).

Other

MeasureTime frameDescription
TV streamingThree weeksThe data, serving as other outcomes are collected within home trials with the test hearing aids, which take place between the weekly study appointments. The participants will be asked to assess the streamed signals in regard to any disturbing artefacts (e. g. fluctuation of volume or sound quality). In case that the participants experienced such artefacts, they will be asked to rate how bothersome these artefacts were (on a 10-point scale from 'not at all - extremely'). These ratings will be aggregated to arrive at one reported value.

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026